Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Key facts
- Where
- Calgary, Edmonton, Hamilton, Québec, Saskatoon, and Vancouver, CanadaSee the 6 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07241546, who can take part
Where in Canada
- CalgaryCalgary, CanadaTaking people
- EdmontonEdmonton, CanadaTaking people
- HamiltonHamilton, CanadaTaking people
- QuébecQuébec, CanadaTaking people
- SaskatoonSaskatoon, CanadaTaking people
- VancouverVancouver, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Arrowhead Pharmaceuticals
- Trial code
- NCT07241546
- Record updated
- 1 October 2026
- Original description
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.Read full original descriptionShow less
A Randomized, Double-blind, Placebo-controlled Phase 2a Study of ARO-RAGE Inhalation Solution to Assess Efficacy on Small Airway Dysfunction in Allergen-induced Mild Asthma
The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.
Inclusion: Clinically stable, mild atopic asthma (FEV1 ≥70% predicted); Established allergy confirmed by positive skin prick test at screening; Willing and able to perform lung function tests and other study-related procedures; Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later.
Exclusion: Concomitant diagnosis of a clinically important pulmonary disease other than asthma; Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma; History or current medical condition contraindicating methacholine challenge; Note: Additional inclusion/exclusion criteria may apply per protocol.